Literature DB >> 10218784

High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity.

K B Burrows1, C K Meshul.   

Abstract

The goal of this study was to determine if high-dose methamphetamine treatment altered presynaptic immunoreactivity for the amino acid neurotransmitters GABA and glutamate within the basal ganglia. Methamphetamine (15 mg/kg every 6 h, four doses) treatment in rats resulted in severe hyperthermia and a long-lasting (four weeks) depletion of striatal dopamine content (>80%). Severe dopamine loss correlated with a decrease in the density of presynaptic immunolabeling for GABA one week post-drug, and an increase after four weeks. Although no changes were seen in presynaptic striatal glutamate immunoreactivity, there was a significant increase in the percentage of glutamate-immuno-positive terminals associated with perforated postsynaptic densities. Rats given the same dose of methamphetamine but prevented from becoming hyperthermic showed less severe dopamine depletions and a lack of ultrastructural or immunocytochemical changes. In addition, induction of hyperthermia in the absence of drug decreased immunolabeling within mitochondria, but had no effect on dopamine content, morphology or nerve terminal immunoreactivity. Altered presynaptic GABA immunolabeling and terminal size were found in both the striatum and globus pallidus, suggesting that dynamic changes occur in the striatopallidal pathway following methamphetamine-induced dopamine loss. In addition, ultrastructural changes in glutamate-positive synapses which have been correlated with increased synaptic activity were found. These results are similar to changes in GABA and glutamate synapses that follow nigrostriatal dopamine loss in 6-hydroxydopamine-lesioned animals and in Parkinson's disease, and provide the first direct evidence that methamphetamine-induced dopamine loss alters the GABAergic striatopallidal pathway. Exposure to either methamphetamine or prolonged hyperpyrexia decreased mitochondrial Immunoreactivity, indicating that hyperthermia may contribute to methamphetamine toxicity by affecting energy stores.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10218784     DOI: 10.1016/s0306-4522(98)00506-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Endogenous dopamine modulates corticopallidal influences via GABA.

Authors:  V V Raevskii; G S Dawe; J D Stevenson
Journal:  Neurosci Behav Physiol       Date:  2003-10

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 3.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

4.  Occurrence of bicuculline-, NMDA- and kainic acid-induced seizures in prenatally methamphetamine-exposed adult male rats.

Authors:  Romana Slamberová; R Rokyta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-25       Impact factor: 3.000

5.  Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum.

Authors:  Despina A Tata; Bryan K Yamamoto
Journal:  Synapse       Date:  2008-05       Impact factor: 2.562

6.  Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity.

Authors:  Marco Bortolato; Roberto Frau; A Paola Piras; William Luesu; Valentina Bini; Giacomo Diaz; Gianluigi Gessa; M Grazia Ennas; M Paola Castelli
Journal:  Neurotox Res       Date:  2009-02-25       Impact factor: 3.911

7.  Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults.

Authors:  Mariana Cherner; Paola Suarez; Corinna Casey; Robert Deiss; Scott Letendre; Thomas Marcotte; Florin Vaida; J Hampton Atkinson; Igor Grant; Robert K Heaton
Journal:  Drug Alcohol Depend       Date:  2009-10-07       Impact factor: 4.492

Review 8.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

9.  Chronic Methamphetamine Effects on Brain Structure and Function in Rats.

Authors:  Panayotis K Thanos; Ronald Kim; Foteini Delis; Mala Ananth; George Chachati; Mark J Rocco; Ihssan Masad; Jose A Muniz; Samuel C Grant; Mark S Gold; Jean Lud Cadet; Nora D Volkow
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.